We hypothesized that antagonizing the IL-6 pathway in CHIP carriers will reduce their risk of cardiovascular disease (CVD) since CHIP speeds up atherosclerosis and elevates IL-6/IL-1 expression in mice [17]. Here, IL6 is linked to atherosclerosis.